US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Annexin reports first imaging-study results in Retinal Vein Occlusion

Annexin Pharmaceuticals AB (“Annexin”) provides an update on its ongoing clinical study in patients with Retinal Vein Occlusion (RVO) using fluorescent labelled ANXV. Images in a case-report of a patient with RVO indicates site-specific accumulation of ANXV in the vessels affected by retinal vein occlusion.Annexin is collaborating with TRACER Europe BV (“TRACER”) and the University Medical Center Groningen (“UMCG”) on an innovative clinical molecular imaging trial. The trial, also referred to as the SIGHT study, uses Annexin’s fluorescently labelled drug candidate ANXV to visualize the

Annexin Pharmaceuticals appoints Susanne Andersson as CFO

Annexin Pharmaceuticals AB (publ) has recruited Susanne Andersson as Chief Financial Officer (CFO).  Susanne will take position as CFO at Annexin Pharmaceuticals during April 2023, joining the management team. She has long-standing experience as CFO with investor relations responsibility from a number of international listed companies in various industries, including Sedana Medical, Pricer, ChromoGenics and Nordic Mines. Susanne’s most recent position was an interim assignment as CFO consultant on Team Interim.  “I want to thank the current CFO Henrik Palm, who will enter into

Annexin appoints Dr. Alain Thibault as Therapeutic Area Head of Oncology.

STOCKHOLM January 18, 2023   Annexin Pharmaceuticals AB (publ) announces that Dr. Thibault, a medical  oncologist with extensive global experience leading novel compounds through clinical development, will join as a new team member and Therapy Area Head, Oncology. Dr Thibault obtained his Medical Degree at McGill University Montreal, Canada and Board Certification in Oncology and Internal Medicine in the US. He has held management and specialist positions at Roche, J&J and Regeneron as well as Chief Medical Officer roles in biotech companies.   “Annexin is now entering the field

Annexin Pharmaceuticals carries out a directed share issue of approximately SEK 7 million to begin development in the cancer field

PRESS RELEASE19 December 2022   The Board of Directors of Annexin Pharmaceuticals AB (publ) (”Annexin Pharmaceuticals” or the “Company”) has today, with the support of the authorization from the annual general meeting held on 24 May 2022, resolved on a directed share issue of 7,368,421 shares with a deviation from the shareholders’ preferential rights, whereby the Company receives approximately SEK 7 million before the costs for the issue, corresponding to a subscription price of SEK 0.95 per share (the “Directed Share Issue”). The Directed Share Issue, which is directed to the five

Annexin receives Innovation Award at an international conference

STOCKHOLM December 14, 2022 Annexin Pharmaceuticals AB (Publ) ("Annexin" or "the Company") announces today that the Company was awarded the Innovation Award at the Ophthalmology Innovation Summit (OIS) in San Diego for its ongoing development of ANXV for retinal vein occlusion (RVO). Dr. Anna Frostegård, Chief Scientific and Medical Officer, presented the RVO program and accepted the award. The jury selecting the award winners comprised investors and analysts with competence in the ophthalmological field (OIS Newsletter 

First patient dosed in Annexin's Phase 2 study in retinal vein occlusion.

STOCKHOLM (8 November 2022) - Annexin Pharmaceuticals AB (publ) (Nasdaq First North Growth market) announces today that the first patient with retinal vein occlusion (RVO) has been dosed in the Company’s Phase 2 clinical study with ANXV.   RVO is one of the most common causes of blindness. Authorized drugs for treatment of RVO are injected directly into the eye and have no direct effect on the blockage of blood vessels that causes the disease. By contrast, the Company’s drug candidate ANXV, which is administered intravenously, has the potential to directly counteract the blockage of

Annexin signs exclusive licensing deal in cancer

Annexin Pharmaceuticals AB (publ) has entered into a license agreement with Stanford University, CA, USA granting Annexin Pharmaceuticals exclusive license to patent rights related to use of Annexin A5 in treatment of cancer.  STOCKHOLM (3 April, 2022) - The license involves a novel therapeutic concept for treating cancer by administration of the Annexin A5 protein, functionally identical to Annexin Pharmaceuticals’ drug candidate ANXV. Studies have shown that Annexin A5 acts as a potent immunomodulating anti-cancer agent acting via blocking phosphatidylserine (PS) on cancer cells (US

Annexin appoints Dr. Mario Fsadni as Head of Ophthalmology

Annexin Pharmaceuticals AB (publ) announces that Dr Mario Fsadni, an ophthalmologist with extensive global experience from leading novel compounds through clinical development into marketed drugs, will join as a new team member and Therapy Area Head, Ophthalmology.STOCKHOLM (29 March, 2022) - Dr. Fsadni, MBChB, MRC Ophth, MSc, LLM, FMH has obtained his Medical Degree and Ophthalmology training in Manchester, UK. He was previously the Global Medical Director at Novartis Ophthalmics and Director Product Development in Ophthalmology at Allergan, before starting a consultancy designed

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe